Comparing Meniscal Repair Biologic Augmentation: Marrow Venting Procedure Versus PRP (MVP Trial)

Launched by UNIVERSITY OF CHICAGO · Feb 24, 2021

Keywords

ClinConnect Summary

The MVP Trial is a clinical study looking at two different methods to help repair tears in the meniscus, which is the cartilage in your knee. Specifically, the trial will compare a procedure called Bone Marrow Venting Procedure (BMVP) with Platelet-Rich Plasma (PRP) injections. Both methods have shown promise in helping meniscal repairs, but this is the first time researchers are directly comparing their effectiveness. The goal is to find out which method works better in preventing repair failures and reducing the need for additional surgeries.

To participate in this study, you must be at least 16 years old and have a specific type of meniscal tear, including various patterns like vertical or oblique tears. Certain other conditions may disqualify you, such as having a previous meniscal surgery on the same knee or significant cartilage damage. If you join the trial, you can expect regular follow-ups with the research team after your treatment to monitor your recovery and help us understand the best ways to treat meniscal tears in the future. This trial is currently recruiting participants of all genders, and it aims to improve care for patients like you who are dealing with knee injuries.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • 1. Age 16 or older
• • 2. Medial, lateral, vertical longitudinal, oblique, or radial meniscal tear
• • 3. Complex tears may be included at the discretion of the site investigator if patient has one of tear patterns listed in inclusion criteria 2 as the most predominant finding
• 4. No other concomitant procedure unless one of the following:
• • Chondroplasty
• • Synovectomy
• • Loose body removal
• • "Contralateral" menisectomy (i.e. medial meniscus repair with a lateral menisectomy or lateral meniscus repair with a medial menisectomy) would be permitted for inclusion
• • Any other procedure that does not include drilling, requires prior approval of the study sponsor for each procedure
• • Exclusion Criteria
• • 1. Patients requiring cartilage restorative or repair procedures (i.e. OCD fixation, micro-fracture repair, or others)
• • 2. Patients with meniscus root tears
• • 3. Patients undergoing repair for horizontal cleavage tears
• • 4. Kellgren-Lawrence scale 3\>
• • 5. Patients undergoing lateral release
• • 6. Ipsilateral chondral lesion with Outerbridge classification of 3-4
• • 7. Use of prednisone or other steroids, any immunosuppressant, or chemotherapy 1-week before surgery or expected use within six weeks after surgery
• • 8. Cortisone use within the six weeks prior to surgery
• • 9. Utilizing worker's compensation at the time of screening
• • 10. Any previous ligament surgery on the index limb. Any previous meniscal surgery on the index meniscus.
• • 11. Concomitant ligamentous insufficiency
• • 12. Inflammatory rheumatic disease or other rheumatic disease
• • 13. Immune compromised patients (hepatitis, HIV, etc.)
• • 14. Any nicotine based products within the three months prior to surgery (including cigarettes, cigars, vaping, nicotaine patch, etc)
• • 15. History of distal femur, proximal tibia, or patellar fracture that was treated operatively
• • 16. Non English-speaking patients